Stephan Busque, MD
Surgery · Stanford, CANPI 1508891052
Payments from drug & device makers
Across 14 payments — averaging $9054.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grifols, S.A.$98K
- Roche Products Limited$20K
- Genentech, Inc.$8K
- Paragonix Technologies, Inc.$195
- Johnson & Johnson$167
- AstraZeneca$150
- plus $12 from 1 others
What the payments were for
- Consulting fees$106,130100%
- Speaking & faculty fees$1500%
- Food & beverage$3610%
- Gifts$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Grifols, S.A. | 1 | $98,186 |
| Roche Products Limited | 5 | $20,110 |
| Genentech, Inc. | 2 | $7,944 |
| Paragonix Technologies, Inc. | 2 | $195 |
| Johnson & Johnson | 2 | $167 |
| AstraZeneca | 1 | $150 |
| Intuitive Surgical | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIRIS$150
- KidneyVault$138
- SURGICEL NU-KNIT$125
- VISTASEAL$125
- STRATAFIX$125
- Echelon Flex$125
- Harmonic$125
How this compares
$126,763 in reported general payments places this provider in the 95th percentile of 2,363 surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VemlidyTenofovir Alafenamide | 11 | $14,024 |
| EliquisApixaban | 16 | $10,779 |
| CreonLipase/Protease/Amylase | 11 | $8,782 |
| Valganciclovir Hcl | 123 | $7,247 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $4,574 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 22 | $3,193 |
| Comfort Ez Pen NeedlePen Needle, Diabetic | 29 | $2,741 |
| Mycophenolate Mofetil | 33 | $2,696 |
| Humalog Kwikpen U-100Insulin Lispro | 17 | $2,469 |
| Entecavir | 22 | $2,237 |
| Ultra-Fine Nano Pen NeedlePen Needle, Diabetic | 32 | $1,941 |
| Novolog FlexpenInsulin Aspart | 13 | $1,749 |
| Insulin Aspart FlexpenInsulin Aspart | 12 | $1,504 |
| Nystatin | 39 | $942 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $929 |
Paid to pharmacies, not to this prescriber.
Other surgery in Stanford
- Brendan VisserStanford$592K
- Timothy ChuterSan Francisco$8.9M
- Peter StockSan Francisco$6.5M
- Santiago HorganSan Diego$2.8M
- Kenneth DeckLaguna Hills$2.4M
- Daniel RiskinSan Jose$2.2M
- Michael DemeureNewport Beach$1.7M
- Rock LiuHayward$1.6M
- David LouriePasadena$1.4M
- Andrea PakulaThousand Oaks$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.